

Ref: STEX/Results/Published-2023-24

Date: 13.02.2024

To

BSE Limited
Floor 25, P J Towers
Dalal Street
Mumbai-400001

National Stock Exchange of India Ltd
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051

BSE Code-531146

NSE Code: MEDICAMEQ

Company Number: 531146

Sub. : Copy of Publication for Un-audited Financial Results for the quarter and nine months ended December 31, 2023

Dear Sir,

Pursuant to regulation 30 & 47 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015 (“the Regulations”), please find enclosed newspaper cutting with regard to the publication of extract of Un-audited Financial Results of the Company for the quarter and nine months ended on December 31, 2023 approved by the Board of Directors at their Meeting held on 12.02.2024.

The copy of the results published in the Financial Express and Jansatta dated February 12, 2024 is enclosed.

This is for your information and records.

Kindly acknowledge the receipt.

Thanking You,

Yours truly,
For Medicamen Biotech Limited

Parul Choudhary
Company Secretary
ACS-44157

Encl: As above.

10 COMPANIES

powered by two-cylinder engines but their capacity is 650cc.

Kawasaki, Benelli, Suzuki and Honda

having this technology below the 850cc category. While India will become the centre for Pierer Mobility for all models

bikes in India, mid-range and premium vehicles in China and premium in Europe," Pierer added.

Puri Buch said.

at the (9.1%), retail investors had said (12.85%), mutual funds earlier (4.99%), body corporates (6.33%) and others.

Also, FDI in fintech firms are governed by separate guidelines issued by the RBI, governing electronic payments, know-your-customer requirements and data localisation.



MEDICAMEN BIOTECH LTD.

Regd. Office: 1506, Chiranjiv Tower 43, Nehru Place, New Delhi-110019

CIN : L74899DL 1993PLC056594 E-mail : cs@medicamen.com, Website: www.medicamen.com

Extracts of Standalone and Consolidated Unaudited Financial Results for the Quarter and Nine Months ended on 31.12.2023
(Rupees in Lakhs) Except per share data

Sl. No.	Particulars	Standalone						Consolidated						
		Three Month Ended			Nine Month Ended			Three Month Ended			Nine Month Ended			Year Ended
		Un-Audited 31.12.2023	Un-Audited 30.09.2023	Un-Audited 31.12.2022	Un-Audited 31.12.2023	Un-Audited 31.12.2022	Audited 31.03.2023	Un-Audited 31.12.2023	Un-Audited 30.09.2023	Un-Audited 31.12.2022	Un-Audited 31.12.2023	Un-Audited 31.12.2022	Audited 31.03.2023	
1	Total income from operations (net)	4503.50	4322.08	3474.42	12913.84	10285.14	14034.62	4733.27	4409.12	3621.05	13374.62	10431.77	14332.96	
2	Net Profit/ (Loss) for the period (before tax, exceptional and/ or Extraordinary items)	400.91	400.04	421.18	1316.28	1268.58	1733.28	327.22	246.45	422.26	1042.00	1268.95	1704.50	
3	Net Profit/ (Loss) for the period before tax (after exceptional and/ or Extraordinary items)	400.91	400.04	421.18	1316.28	1268.58	1733.28	327.22	246.45	422.26	1042.00	1268.95	1704.50	
4	Net Profit/ (Loss) for the period after tax (after exceptional and/ or Extraordinary items)	276.63	301.16	375.94	1019.49	1095.61	1500.20	202.99	147.67	377.02	745.36	1095.98	1472.85	
5	Total comprehensive income for the period (Comprising Profit/ (loss) for the period (after tax) and other Comprehensive income (after tax))	276.63	301.16	375.94	1019.49	1095.61	1500.20	202.99	147.67	377.02	745.36	1095.98	1472.85	
6	Equity Share Capital	1265.11	1265.11	1265.11	1265.11	1265.11	1265.11	1265.11	1265.11	1265.11	1265.11	1265.11	1265.11	
7	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)													
8	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operation)													
	Basic:	2.19	2.38	2.97	8.06	8.66	12.04	1.60	1.17	2.98	5.89	8.66	11.82	
	Diluted:	2.19	2.38	2.97	8.06	8.66	12.04	1.60	1.17	2.98	5.89	8.66	11.82	

Note:

- The Un-audited financial results for the quarter and nine months ended on 31.12.2023 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 12th Feb 2024
- This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- The company operates only in one business segment, viz. Pharmaceuticals formulations, hence segment reporting is not applicable
- The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33 - Earning per Share
- The results are not comparable on quarterly or yearly basis as company is regularly incurring capex and filling dossiers with regulatory authorities.
- Limited review report has been carried out by the Statutory Auditors for the above period.
- The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.

Place : New Delhi
Date : 12.02.2024

For Medicamen Biotech Limited
Sd/-
Rahul Bishnoi
Chairman

For and on behalf of the Board
Sd/-
Anil Moolchandani
(Chairman and Managing Director)
DIN- 00022693

TED

Gurugram, Haryana-122050
es@archiesonline.com, Tel: +91 124 4966666
e Months ended 31 December 2023 (₹ in Lakhs)

	Nine Months ended		Year Ended	
	31.12.2022	31.12.2023	31.12.2022	31.03.2023
	Unaudited	Unaudited	Unaudited	Audited
23	2342.59	5826.84	6536.48	8603.33
31	47.23	19.03	(28.21)	111.47
31	47.23	19.03	(28.21)	111.47
27	35.05	40.29	(3.70)	240.75
16	24.18	43.24	(19.41)	151.65
32	675.62	675.62	675.62	675.62
				8,870.71
33	0.10	0.12	(0.01)	0.71
33	0.10	0.12	(0.01)	0.71

ended Unaudited Financial Results filed with the Stock Exchanges Regulations, 2015. The full format of the Quarter Unaudited Financial Results is available on the BSE India Stock Exchange websites viz www.bseindia.com and

Investor grievance Email Address: investor.relations@swarajshares.com
SEBI Registration Number: INM00012980
Validity: Permanent

Date: Monday, February 12, 2024
Place: Mumbai

For and on behalf of all Acquirers
Sd/-
Mr. Rajan Kantil Shah

Place: New Delhi
Date: 12.02.2024

For Newage Marketing Ltd
Manish
Chairman & Managing Director
DN: 003

(0.63)	0.48	0.10	(0.16)	0.17	20.25
(0.63)	0.48	0.10	(0.16)	0.17	20.25

detailed format of Financial Results for the third quarter and nine months ended 31st December 2023 under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) 2015. Financial Results for the third quarter and nine months ended 31st December, 2023 are available on the company's website (www.atlantic-commercial.com) and on the company's website (www.atlantic-commercial.com).

For Atlantic Commercial Company Limited

sd/-

Narendra Kishore Gaur

Chairman

DIN - 00168265



MEDICAMEN BIOTECH LTD.

Regd. Office: 1506, Chiranjiv Tower 43, Nehru Place, New Delhi-110019

CIN : L74899DL 1993PLC056594 E-mail : cs@medicamen.com, Website: www.medicamen.com

Extracts of Standalone and Consolidated Unaudited Financial Results for the Quarter and Nine Months ended on 31.12.2023

(Rupees in Lakhs) Except per share data

Sl. No.	Particulars	Standalone						Consolidated					
		Three Month Ended			Nine Month Ended			Three Month Ended			Nine Month Ended		
		Un-Audited 31.12.2023	Un-Audited 30.09.2023	Un-Audited 31.12.2022	Un-Audited 31.12.2023	Un-Audited 31.12.2022	Audited 31.03.2023	Un-Audited 31.12.2023	Un-Audited 30.09.2023	Un-Audited 31.12.2022	Un-Audited 31.12.2023	Un-Audited 31.12.2022	Audited 31.03.2023
1	Total income from operations (net)	4503.50	4322.08	3474.42	12913.84	10285.14	14034.62	4733.27	4409.12	3621.05	13374.62	10431.77	14332.96
2	Net Profit/ (Loss) for the period (before tax, exceptional and/ or Extraordinary items)	400.91	400.04	421.18	1316.28	1268.58	1733.28	327.22	246.45	422.26	1042.00	1268.95	1704.50
3	Net Profit/ (Loss) for the period before tax (after exceptional and/ or Extraordinary items)	400.91	400.04	421.18	1316.28	1268.58	1733.28	327.22	246.45	422.26	1042.00	1268.95	1704.50
4	Net Profit/ (Loss) for the period after tax (after exceptional and/ or Extraordinary items)	276.63	301.16	375.94	1019.49	1095.61	1500.20	202.99	147.67	377.02	745.36	1095.98	1472.85
5	Total comprehensive income for the period (Comprising Profit/ (loss) for the period (after tax) and other Comprehensive income (after tax))	276.63	301.16	375.94	1019.49	1095.61	1500.20	202.99	147.67	377.02	745.36	1095.98	1472.85
6	Equity Share Capital	1265.11	1265.11	1265.11	1265.11	1265.11	1265.11	1265.11	1265.11	1265.11	1265.11	1265.11	1265.11
7	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)												
8	Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operation)												
	Basic:	2.19	2.38	2.97	8.06	8.66	12.04	1.60	1.17	2.98	5.89	8.66	11.82
	Diluted:	2.19	2.38	2.97	8.06	8.66	12.04	1.60	1.17	2.98	5.89	8.66	11.82

Note:

- The Un-audited financial results for the quarter and nine months ended on 31.12.2023 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 12th Feb 2024
- This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- The company operates only in one business segment, viz. Pharmaceuticals formulations, hence segment reporting is not applicable
- The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33 - Earning per Share
- The results are not comparable on quarterly or yearly basis as company is regularly incurring capex and filling dossiers with regulatory authorities.
- Limited review report has been carried out by the Statutory Auditors for the above period.
- The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.

For Medicamen Biotech Limited

Sd/-
Rahul Bishnoi
Chairman

Place : New Delhi
Date : 12.02.2024



The most special way to say you care

आर्चीज लिमिटेड

रजिस्ट्रार : एल36999एचआर1980पीएलसी041175

नंबर 191-एफ, सेक्टर-4, आई.एम.टी. मानेसर, गुरुग्राम, हरियाणा-122050

www.archiesinvestors.in ई-मेल - archies@archiesonline.com, फोन नंबर 91 124 4066666

ती और नौ माह हेतु अलेखापरीक्षित वित्तीय परिणामों का विवरण (रु. लाख में)

	तिमाही समाप्त			नौ माह समाप्त			वर्ष समाप्त
	31-12-2023 (अलेखापरीक्षित)	30-09-2023 (अलेखापरीक्षित)	31-12-2022 (अलेखापरीक्षित)	31-12-2023 (अलेखापरीक्षित)	31-12-2022 (अलेखापरीक्षित)	31-03-2023 (अलेखापरीक्षित)	31-03-2023 (अलेखापरीक्षित)
समाप्त असाधारण	2105.57	2219.63	2342.59	5826.84	6536.48	8603.33	
प्रत्येक	97.42	93.81	47.23	19.03	(28.21)	111.47	
प्रत्येक	97.42	93.81	47.23	19.03	(28.21)	111.47	
प्रत्येक	64.75	112.27	35.05	40.29	(3.70)	240.75	
प्रत्येक	65.33	113.16	24.18	43.24	(19.41)	151.65	
प्रत्येक	675.62	675.62	675.62	675.62	675.62	675.62	
प्रत्येक						8,870.71	
प्रत्येक	0.19	0.33	0.10	0.12	(0.01)	0.71	
प्रत्येक	0.19	0.33	0.10	0.12	(0.01)	0.71	

कंपीकरण अर्थात् विनियमावली, 2015 के विनियम 33 के तहत स्टॉक एक्सचेंज में प्रस्तुत किए गए समाप्त माह के विस्तृत प्रारूप का संक्षिप्त विवरण है। समाप्त तिमाही और नौ माह हेतु अलेखापरीक्षित वित्तीय परिणामों का विवरण www.bseindia.com तथा www.nseindia.com पर और कम्पनी की वेबसाइट www.archiesinvestors.in पर उपलब्ध है।

कृते एवं हिते बोर्ड

हस्ता/-

अनिल मूलचंदानी

(अध्यक्ष एवं प्रबंध निदेशक)

डीआईएन - 00022893